WallStSmart

Alcon AG (ALC)vsDaxor Corporation (DXR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 39842538% more annual revenue ($10.63B vs $26,690). DXR leads profitability with a 34359.0% profit margin vs 7.7%. DXR trades at a lower P/E of 6.5x. ALC earns a higher WallStSmart Score of 49/100 (D+).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 4.5Value: 3.3Quality: 6.8
Piotroski: 3/9

DXR

Hold

45

out of 100

Grade: D+

Growth: 4.7Profit: 5.5Value: 6.7Quality: 6.0
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-24.0%)

Margin of Safety

-24.0%

Fair Value

$64.04

Current Price

$66.81

$2.77 premium

UndervaluedFair: $64.04Overvalued

Intrinsic value data unavailable for DXR.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

DXR6 strengths · Avg: 9.8/10
P/E RatioValuation
6.5x10/10

Attractively priced relative to earnings

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Profit MarginProfitability
34359.0%10/10

Keeps 34359 of every $100 in revenue as profit

EPS GrowthGrowth
329.3%10/10

Earnings expanding 329.3% YoY

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

Return on EquityProfitability
3.7%3/10

ROE of 3.7% — below average capital efficiency

Profit MarginProfitability
7.7%3/10

7.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

DXR4 concerns · Avg: 2.5/10
Market CapQuality
$61.88M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Revenue GrowthGrowth
-82.6%2/10

Revenue declined 82.6%

Free Cash FlowQuality
$-297,4702/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Price/Book, Debt/Equity.

Bull Case : DXR

The strongest argument for DXR centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 34359.0% and operating margin at -9661.0%.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, Return on Equity, Profit Margin. A P/E of 40.7x leaves little room for execution misses.

Bear Case : DXR

The primary concerns for DXR are Market Cap, Piotroski F-Score, Revenue Growth.

Key Dynamics to Monitor

ALC profiles as a value stock while DXR is a declining play — different risk/reward profiles.

ALC carries more volatility with a beta of 0.70 — expect wider price swings.

ALC is growing revenue faster at 9.4% — sustainability is the question.

ALC generates stronger free cash flow (274M), providing more financial flexibility.

Bottom Line

ALC scores higher overall (49/100 vs 45/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Daxor Corporation

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?